Innovative Cellular Therapeutics Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2008)

Organization Overview

First Clinical Trial
2015
NCT02813837
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Innovative Cellular Therapeutics Co., Ltd. | Innovative Cellular Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

cd19 car-t cells (2 trials)

Drugs in Phase 1 Trials (2)

gcc19cart (1 trial)

gucy2c cart cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3